扎鲁替尼治疗iga筛选淋巴浆细胞性淋巴瘤的疗效和安全性

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI:10.26502/jcsct.5079151

G. Zamprogna, Anna Maria Frustaci, M. Deodato, H. Allewelt, D. Weber, C. Rigamonti, A. Tedeschi

{"title":"扎鲁替尼治疗iga筛选淋巴浆细胞性淋巴瘤的疗效和安全性","authors":"G. Zamprogna, Anna Maria Frustaci, M. Deodato, H. Allewelt, D. Weber, C. Rigamonti, A. Tedeschi","doi":"10.26502/jcsct.5079151","DOIUrl":null,"url":null,"abstract":"Efficacy and Safety of zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma. Journal of Cancer Science and Clinical Therapeutics 6 (2022): 146-151. Abstract Non IgM-Lymphoplasmacytic Lymphoma (LPL) is a rare chronic lymph proliferative disorder with worse outcome with respect to classical LPL and Waldenstrom Macroglobulinemia. Therapeutic options are limited and differently from other indolent lymphomas no specific approved therapies are available. Here we present the case of a IgA-secreting LPL previously treated with 6 lines of therapies including immuno-chemotherapy, proteasome inhibitor and radiotherapy. At the last relapse this patient was","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy and Safety of Zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma\",\"authors\":\"G. Zamprogna, Anna Maria Frustaci, M. Deodato, H. Allewelt, D. Weber, C. Rigamonti, A. Tedeschi\",\"doi\":\"10.26502/jcsct.5079151\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Efficacy and Safety of zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma. Journal of Cancer Science and Clinical Therapeutics 6 (2022): 146-151. Abstract Non IgM-Lymphoplasmacytic Lymphoma (LPL) is a rare chronic lymph proliferative disorder with worse outcome with respect to classical LPL and Waldenstrom Macroglobulinemia. Therapeutic options are limited and differently from other indolent lymphomas no specific approved therapies are available. Here we present the case of a IgA-secreting LPL previously treated with 6 lines of therapies including immuno-chemotherapy, proteasome inhibitor and radiotherapy. At the last relapse this patient was\",\"PeriodicalId\":73634,\"journal\":{\"name\":\"Journal of cancer science and clinical therapeutics\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of cancer science and clinical therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26502/jcsct.5079151\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer science and clinical therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26502/jcsct.5079151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

扎鲁替尼治疗iga筛选淋巴浆细胞性淋巴瘤的疗效和安全性。中国医学杂志，2014(6):344 - 344。非igm淋巴浆细胞性淋巴瘤(LPL)是一种罕见的慢性淋巴增生性疾病，与经典LPL和Waldenstrom巨球蛋白血症相比，预后更差。治疗选择是有限的，与其他惰性淋巴瘤不同，没有特定的批准治疗方法。在这里，我们提出了一个iga分泌性LPL的病例，以前用6种治疗方法治疗，包括免疫化疗，蛋白酶体抑制剂和放疗。在最后一次复发时，这个病人

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy and Safety of Zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma

Efficacy and Safety of zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma. Journal of Cancer Science and Clinical Therapeutics 6 (2022): 146-151. Abstract Non IgM-Lymphoplasmacytic Lymphoma (LPL) is a rare chronic lymph proliferative disorder with worse outcome with respect to classical LPL and Waldenstrom Macroglobulinemia. Therapeutic options are limited and differently from other indolent lymphomas no specific approved therapies are available. Here we present the case of a IgA-secreting LPL previously treated with 6 lines of therapies including immuno-chemotherapy, proteasome inhibitor and radiotherapy. At the last relapse this patient was

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of cancer science and clinical therapeutics

自引率

0.00%

发文量